


Overview of the Project

Klaus Pantel - Coordinator
Universitaetsklinikum Hamburg-Eppendorf (UKE), Germany

Main objective:

To provide a minimally invasive blood test using a comprehensive panel of **liquid biopsy** diagnostics (LBx) for **early detection of pancreatic cancer** (PDAC) and the malignant conversion of premalignant to invasive lesions.

Background and relevance



- PDAC is one of the **most lethal cancers** in Europe
- Early detection of PDAC is rare
- **LBx** opens new diagnostic avenues to reduce PDAC mortality

1974-2020 Data from National Cancer Institute (NCI) | Siegel *et al.*, Cancer Statistics 2021

REVIEW


Open Access

Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer – a comprehensive review



Kim-Lea Reese¹, Klaus Pantel^{1*} and Daniel J. Smit^{1*}

- Provides overview of different liquid biopsy biomarkers for the early diagnosis of PDAC
- Discusses the validity of multimarker panels



Consortium and partners



Coordinator:

Prof. Dr. Klaus Pantel

Universitaetsklinikum Hamburg-Eppendorf (UKE)

Co-Coordinator:

Prof. Dr. Matthias Löh

Karolinska Institutet (KI)

Project duration

5 years

Project start


1st January 2023

8 countries

18 institutions

Grant amount

EUR 9.8 million



The consortium's expertise




PANCAID's a team of world-class experts in translational research on PDAC, liquid biopsy, data handling and computational data analysis, health economy as well as ethical aspects of cancer screening



EXPERTISE	PARTNERS
Liquid biopsy (CTC, EV, ctDNA)	UKE, MUG, HUJI, CNIO, UCAM, KI, UU, CHU, UKHD
Pancreatic cancer patient care	KI, Umeå, CNIO, UKHD, MACCABI, UKSH, FIBIRCYS
Risk group maintenance (IAR, IPMN)	KI, Umeå, CNIO, UKHD
Genetic aspects	MUG, KI, CNIO
Data collection and analysis	CMR, CNIO, HUJI
Health economy	UKE, KI, CMR
Ethics	KI, PCE, MACCABI
Dissemination, communication, open science practices	concentris, PCE
Digital software products	ZAVA
Exploitation, innovation management and intellectual property	UKE (ELBS), concentris
Project management and coordination	concentris, UKE, KI



Project Structure and Governance | Overview



Project Structure – Workflow



→ Strong interdependence between WPs!

0 **Methodological pre-study** comparing different LBx methods on the same samples to identify the best method(s) suitable for stored samples

2 Retrospective analysis of samples (LBx, tissue) from **main duct IPMN**

4 Retrospective analysis of samples (LBx [tissue]) from individuals at risk for **IPMN**

6 Retrospective analysis of sequential samples collected in **individuals** in which some **developed PDAC**

1 **Retrospective** analysis of samples (LBx, tissue) with **limited disease = early PDAC**


3 Retrospective analysis of samples (LBx [tissue]) from **branched duct IPMN**

5 Retrospective analysis of samples (LBx [tissue]) from patients with **chronic pancreatitis, aged 55-65, heavy smokers, and newly onset diabetes mellitus**

7 **Prospective pilot study** in **high-risk individuals** during the course of PANCAID

8 Protocol for a prospective randomized clinical study investigating **the optimal LBx method(s), endpoint resection rate**


Impact and benefits



- › **Scientific:** New breakthrough scientific discovery on biology of PDAC development
- › **Economic/Technological:** New cancer screening blood test for PDAC opening a new market of LBx
- › **Medical:** High-impact consortium tackling the challenge of early detection and improved treatment of PDAC
- › **Societal:** Reduced mortality and higher life quality for PDAC patients
- › **SMEs** contributing to PANCAID: concentris, CMR, Zava → so far positive effect on employment, financial stability, and profitability

Key innovations / Expected outcomes

- Successful interlaboratory validation of LBx test for PDAC.
- Novel composite biomarker blood test.
- Definition of the target population (end-user) based on the socio-economic and ethical assessments.
- Database and biobank will be made available to other scientific projects.




Dissemination and communication

- Exploitation through patenting the novel blood test.
- Dissemination towards the scientific community and industry.
- Communication towards citizens and patients (involving patient advocacy groups & patient organisation PCE).
- Communication towards policy makers.



Synergies and cancer cluster



Further information:

PANCAID website





ISMRC 2025

14th International Symposium
on Minimal Residual Cancer

Liquid Biopsy: From Discovery to
Clinical Implementation

7 – 9 May 2025
Hyatt Regency Nice Palais de la Méditerranée
Nice, France



www.ismrc-symposium.eu



Prof. Dr. Paul Hofman
Congress Chair

Prof. Dr. Catherine
Alix-Panabières, Co-Chair

Prof. Dr. med.
Klaus Pantel, Co-Chair



Confirmed Speakers

Catherine Alix-Panabières, France	Laura Keller, France
Fabrice André, France	Sonja Loges, Germany
Benjamin Besse, France	Raphael Lopez Lopez, Spain
Joanna Budna, Poland	Umberto Malapelle, Italy
Luis Diaz, USA	Nuria Malats, Spain
Yuval Dor, Israel	Joan Massagué, USA
Janine Erler, Denmark	Clara Montagut, Spain
Sidonia Fagarasan, Japan	Nickolas Papadopoulos, USA
Karen-Lise Garm-Spindler, Denmark	Klaus Pantel, Germany
Paola Gazzaniga, Italy	Jean-Yves Pierga, France
Christoffer Gebhardt, Germany	Carolin Sauer, United Kingdom
An Hendrix, Belgium	Charles Swanton, United Kingdom
Paul Hofman, France	Jean-Paul Thiery, France
Simon Heeke, USA	

Chair

Prof. Dr. Paul Hofman
IHU RespirERA, CHU of Nice, France



Co-Chairs

Prof. Dr. med. Klaus Pantel
Institute of Tumor Biology, University
Medical Center Hamburg-Eppendorf, Germany

Prof. Dr. Catherine Alix-Panabières
Laboratoire Cellules Circulantes, Rares
Humaines (LCCRH), CHU de Montpellier, France



www.ismrc-symposium.eu





The PANCAID team

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.



Funded by
the European Union